Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MEDI raises second quarter guidance

MedImmune (MEDI) raised its second quarter EPS estimate to $0.02-$0.05 from $0.00-$0.02 to account for continued

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE